GlaxoSmithKline PLC (NYSE:GSK) major shareholder Plc Glaxosmithkline purchased 428,571 shares of the business’s stock in a transaction dated Monday, November 6th. The stock was bought at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

GlaxoSmithKline PLC (NYSE:GSK) traded down $0.32 during trading on Tuesday, reaching $35.82. The company’s stock had a trading volume of 4,914,490 shares, compared to its average volume of 5,470,000. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96. The stock has a market cap of $86,680.00, a P/E ratio of 12.82, a PEG ratio of 2.00 and a beta of 1.00. GlaxoSmithKline PLC has a twelve month low of $35.70 and a twelve month high of $44.53.

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 11th. Shareholders of record on Friday, November 10th will be paid a dividend of $0.5037 per share. This represents a $2.01 annualized dividend and a yield of 5.63%. The ex-dividend date of this dividend is Thursday, November 9th. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. GlaxoSmithKline PLC’s payout ratio is presently 158.40%.

COPYRIGHT VIOLATION NOTICE: “GlaxoSmithKline PLC (GSK) Major Shareholder Plc Glaxosmithkline Acquires 428,571 Shares” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/11/08/glaxosmithkline-plc-gsk-major-shareholder-plc-glaxosmithkline-acquires-428571-shares.html.

GSK has been the topic of a number of analyst reports. TheStreet upgraded GlaxoSmithKline PLC from a “c+” rating to a “b” rating in a report on Wednesday, October 25th. Zacks Investment Research upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price target on the stock in a report on Tuesday, July 18th. Argus restated a “buy” rating and set a $50.00 target price on shares of GlaxoSmithKline PLC in a research note on Thursday, August 31st. Investec downgraded GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Monday. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Wednesday, October 18th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $44.33.

A number of institutional investors have recently bought and sold shares of GSK. Renaissance Technologies LLC grew its stake in GlaxoSmithKline PLC by 112.1% during the 2nd quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock valued at $402,655,000 after purchasing an additional 4,935,900 shares during the last quarter. FMR LLC grew its stake in GlaxoSmithKline PLC by 5.9% during the 2nd quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock valued at $1,079,047,000 after purchasing an additional 1,389,238 shares during the last quarter. Federated Investors Inc. PA grew its stake in GlaxoSmithKline PLC by 22.7% during the 2nd quarter. Federated Investors Inc. PA now owns 4,511,155 shares of the pharmaceutical company’s stock valued at $194,521,000 after purchasing an additional 833,501 shares during the last quarter. Marshall Wace North America L.P. grew its stake in GlaxoSmithKline PLC by 148.0% during the 2nd quarter. Marshall Wace North America L.P. now owns 1,119,491 shares of the pharmaceutical company’s stock valued at $48,138,000 after purchasing an additional 668,088 shares during the last quarter. Finally, Fisher Asset Management LLC grew its stake in GlaxoSmithKline PLC by 4.7% during the 2nd quarter. Fisher Asset Management LLC now owns 12,534,385 shares of the pharmaceutical company’s stock valued at $540,483,000 after purchasing an additional 564,519 shares during the last quarter. Institutional investors and hedge funds own 9.29% of the company’s stock.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.